Table 3.
Imaging and pathologic characteristics for patients who each exhibited a single identifiable lesion on pre-transplant imaging (N=316).
| No TIPS (n=303) |
TIPS (n=13) |
P value | |
|---|---|---|---|
|
| |||
| Age at transplant, Median (IQR) | 58.6 (53.7–64.3) | 59.5 (53.0–65.0) | 0.90 |
|
| |||
| Male gender, N (%) | 240 (79.2%) | 12 (92.3%) | 0.25 |
|
| |||
| Etiology, N (%) | |||
| Hepatitis C | 220 (72.6%) | 10 (76.9%) | 0.73 |
| Hepatitis B | 25 (8.3%) | 0 (0.0%) | 0.28 |
| Alcohol | 19 (6.3%) | 1 (7.7%) | 0.85 |
| Autoimmune | 7 (2.3%) | 0 (0.0%) | 0.58 |
| Non-alcoholic steatohepatitis | 7 (2.3%) | 0 (0.0%) | 0.58 |
| Cryptogenic/other | 18 (5.9%) | 1 (7.7%) | 0.80 |
|
| |||
| MELD | |||
| Allocation, Median (IQR) | 28 (24–29) | 27 (22–29) | 0.63 |
| Biochemical, Median (IQR) | 12 (9–16) | 14 (13–17) | 0.04 |
| Exception granted, N (%) | 273 (90.4%) | 10 (76.9%) | 0.12 |
|
| |||
| AFP (ng/mL), Median (IQR) | |||
| At time of listing | 12 (5–43) | 6.0 (3–35) | 0.36 |
| Highest prior to transplant | 16 (6–71) | 34 (10–84) | 0.38 |
| Most recent prior to transplant | 9.0 (4–27) | 17 (6–41) | 0.24 |
|
| |||
| Days on waitlist, Median (IQR) | 215 (82–404) | 349 (147–724) | 0.08 |
|
| |||
| Pre-transplant treatment, N (%) | |||
| None | 61 (20.3%) | 5 (38.5%) | 0.12 |
| TACE | 209 (69.0%) | 6 (46.2%) | 0.08 |
| RFA | 48 (15.8%) | 3 (23.1%) | 0.49 |
| Resection | 5 (1.7%) | 0 (0.0%) | 0.64 |
| Radioembolization | 0 (0.0%) | 0 (0.0%) | 0.99 |
| Percutaneous ethanol injection | 0 (0.0%) | 0 (0.0%) | 0.99 |
| Number of treatments | 1 (1–1) | 1 (0–1) | 0.06 |
|
| |||
| Most recent pre-transplant imaging, N (%) | |||
| MRI | 252 (83.4%) | 11 (84.6%) | 0.92 |
| CT | 27 (8.9%) | 1 (7.7%) | 0.88 |
| Ultrasound | 4 (1.3%) | 1 (7.7%) | 0.34 |
|
| |||
| Days from imaging to transplant, Median (IQR) | 46 (26–74) | 54 (34–90) | 0.66 |
|
| |||
| Pre-transplant imaging | |||
| Diameter of lesion (mm), Median (IQR) | 22 (16–33) | 24 (20–38) | 0.29 |
|
| |||
| Explant evaluation | |||
| Number of lesions, Median (IQR) | 1 (1–2) | 2 (1–3) | 0.02 |
| Diameter (mm) of dominant lesion, Median (IQR) | 25 (18–35) | 29 (25–35) | 0.36 |
| Occult disease | 104 (34.3%) | 8 (61.5%) | 0.049 |
| Outside Milan criteria, N (%) | 51 (16.8%) | 7 (53.9%) | <0.001 |
| Four or more lesions, N (%) | 18 (5.9%) | 3 (23.1%) | 0.02 |
AFP = alpha-fetoprotein. CT = computerized tomography. IQR = interquartile range. MELD = Model for End-Stage Liver Disease. MRI = magnetic resonance imaging. N= number. RFA = radiofrequency ablation. TACE = trans-arterial chemoembolization.